Liver Cancer
Copyright ©The Author(s) 2003.
World J Gastroenterol. Dec 15, 2003; 9(12): 2676-2680
Published online Dec 15, 2003. doi: 10.3748/wjg.v9.i12.2676
Figure 1
Figure 1 A: Images in a ACI rat with a solid HCC in group B. (a) Pretherapy did not enhance T1-weighted MR imaging with SE sequence (460/15). It shows a small hypointense tumor (arrow) in the left lateral lobe of liver; B: Pretherapeutic unenhanced T2-weighted MR imaging with TSE sequence (3170/99). The hyperintense lesion with a size of 0.44×0.40 mm2 (arrow) is well discern-ible from the surrounding liver tissue. C: Images in a ACI rat with a solid HCC in group B. (a) Posttherapy did not enhance T1-weighted MR imaging with SE sequence (460/15). It shows a small hypointense tumor (arrow) in the left lateral lobe of liver. D: Unenhanced T2-weighted MR imaging with TSE sequence (3170/99) after therapy. It shows the inhomogeneous hyperintense lesion with a size of 0.44 × 0.38 mm2 (arrow) and demonstrates that there is no difference between the tumor volume before and after therapy.